BRAINSTORM CELL THERAPEUTICS INC
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Interim Condensed Consolidated Statements of Cash Flows
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Nine months ended · · Three months ended | ||||||||||||
| · · September 30, · · September 30, | ||||||||||||
| · 2024 · 2023 · 2024 · 2023 | ||||||||||||
| Cash flows from operating activities: | | | | | ||||||||
| | | | | | | | | | | | | |
| Net loss | | $(8,650) | | $(11,614) | | $(2,708) | | $(1,226) | ||||
| | | | | | | | | | | | | |
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | | | |||||
| Depreciation | | 187 | | | 199 | | | 59 | | | 65 | |
| Stock-based compensation related to options granted to employees and directors | | 542 | | | 1,540 | | | 178 | | | 548 | |
| Change in operating lease liability | | | 23 | | | (183) | | | 30 | | | (58) |
| Decrease in other accounts receivable and prepaid expenses | | 403 | | | 4 | | | 149 | | | 345 | |
| Increase (decrease) in trade payables | | | (351) | | | (298) | | | (737) | | | (1,264) |
| Loss (gain) on change in fair value of warrants (Note 6) | | | 135 | | | (4,761) | | | (394) | | | (4,761) |
| Increase (decrease) in other accounts payable and accrued expenses | | (334) | | | (60) | | | 124 | | | (58) | |
| Total net cash used in operating activities | | $(8,045) | | $(17,173) | | $(3,299) | | $(6,409) | ||||
The accompanying notes are an integral part of the consolidated financial statements.
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Nine months ended · · Three months ended | ||||||||||||
| · · September 30, · · September 30, | ||||||||||||
| · 2024 · 2023 · 2024 · 2023 | ||||||||||||
| Cash flows from investing activities: | | | (18) | | | (18) | ||||||
| Changes in short-term deposit | | — | | | 2,015 | | | — | | | 6 | |
| Total net cash provided by investing activities | | $— | | $1,997 | | $— | | $(12) | ||||
| Cash flows from financing activities: | | | | | ||||||||
| Proceeds from issuance of shares in at-the-market (ATM) offering (Note 7) | | | 3,264 | | | 8,529 | | | — | | | — |
| Proceeds from Issuance of shares for private placement (Note 7) (*) | | | 3,645 | | | 7,097 | | | — | | | 7,097 |
| Total net cash provided by financing activities | | $6,909 | | $15,626 | | $— | | $7,097 | ||||
| | | | | | | | | | | | | |
| Increase (decrease) in cash, cash equivalents and restricted cash | | (1,136) | | | 450 | | | (3,299) | | | 676 | |
| | | | | | | | | | | | | |
| Cash, cash equivalents and restricted cash at the beginning of the period | | $1,485 | | $772 | | $3,648 | | $546 | ||||
| | | | | | | | | | | | | |
| Cash, cash equivalents and restricted cash at end of the period | | $349 | | $1,222 | | $349 | | $1,222 | ||||
(*)Presented after neutralizing costs of issuance.
The accompanying notes are an integral part of the consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.